share_log

HC Wainwright & Co. Initiates Coverage On ZyVersa Therapeutics With Buy Rating, Announces Price Target of $2.5

Benzinga ·  Sep 8, 2023 06:59

HC Wainwright & Co. analyst Ed Arce initiates coverage on ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy rating and announces Price Target of $2.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment